Kiadis Pharma announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at t...
14 Maio 2020 - 10:15AM
Amsterdam, The Netherlands, May 14, 2020 –
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces that three abstracts
related to Kiadis’ natural killer (K-NK) cell therapy program have
been accepted for presentation at the virtual edition of the 25th
European Hematology Association (EHA) Congress taking place June 11
– 14, 2020.
The EHA abstracts are now available at www.ehaweb.org. Details
of the presentations are as follows:
· Abstract #S284: This oral presentation
will show clinical data that FC21-NK cells persist in vivo.
Abstract Details Title:
Early-phase Clinical Trials of Adoptive Transfer of Hyperfunctional
NK Cells Expanded Ex Vivo with IL-21 Demonstrate Functional,
Phenotypic, and Haplotype-specific evidence of in vivo
persistencePresenter: Dean Lee, MD,
PhDSession title: Immunotherapy – Clinical
· Abstract #EP1487: This poster will
present data from product samples to show that NK cells expanded
with FC21 or PM21 are distinct from non-expanded NK cells in
phenotype and gene expression signature and are highly cytotoxic,
with elevated levels of cytokines.
Abstract Details Title: Deep
Characterization of MBIL21 Ex Vivo-expanded NK Cells Using Mass
Cytometry, Functional Assays, and RNA Sequencing Establishes
Product Consistency Across Different Manufacturing Sites and
SystemsPresenter: Dean Lee, MD, PhDSession
title: Gene therapy, cellular immunotherapy and
vaccination - Biology & Translational Research
· Abstract #EP585: This poster presents
clinical data of a subset of R/R AML patients treated with FC21-NK
that were enrolled in a phase I/II study with concomitant
infections.
Abstract Details Title:
Clinical and Radiologic Resolution of Infections During Treatment
with MBIL-21-expanded CD56Bright/CD16Bright NK Cells in Patients
with Relapsed or Refractory Acute Myeloid Leukemia (R/R
AML)Presenter: Lucia Mariano da Rocha Silla, MD,
PhDSession title: Acute myeloid leukemia –
Clinical
Kiadis Pharma contacts
Kiadis Pharma:
Maryann Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617)
710-7305 m.cimino@kiadis.com |
Optimum Strategic
Communications: Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144 David Brilleslijper (Amsterdam) Tel: +31 610
942 514 kiadis@optimumcomms.com |
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haplo
donor cell therapy products for the treatment of liquid and solid
tumors as adjunctive and stand-alone therapies.
The Company’s NK-cell PM21 particle technology enables improved
ex vivo expansion and activation of anti-cancer cytotoxic NK-cells
supporting multiple high-dose infusions. Kiadis Pharma’s
proprietary off-the-shelf NK-cell platform is based on NK-cells
from unique universal donors. The Kiadis Pharma off-the-shelf K-NK
platform can make NK-cell therapy product rapidly and economically
available for a broad patient population across a potentially wide
range of indications.
Kiadis Pharma is clinically developing K-NK003 for the treatment
of relapse/refractory acute myeloid leukemia. The Company is also
developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About Kiadis PharmaFounded in 1997, Kiadis
Pharma is building a fully integrated biopharmaceutical company
committed to developing innovative therapies for patients with
life-threatening diseases. With headquarters in Amsterdam, the
Netherlands, and offices and activities across the United States,
Kiadis Pharma is reimagining medicine by leveraging the natural
strengths of humanity and our collective immune system to source
the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext
Amsterdam and Euronext Brussels since July 2, 2015, under the
symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person’s officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking
statements contained in this press release or the actual occurrence
of the anticipated or implied developments. You should not place
undue reliance on forward-looking statements, which speak only as
of the date of this press release.